A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges

Nature

Volumn 533, Issue 7601, 2016, Pages 105-109

  Gautam, Rajeev ^a   Nishimura, Yoshiaki ^a   Pegu, Amarendra ^a   Nason, Martha C ^a   Klein, Florian ^b,c,d   Gazumyan, Anna ^b   Golijanin, Jovana ^b   Buckler White, Alicia ^a   Sadjadpour, Reza ^a   Wang, Keyun ^a,e   Mankoff, Zachary ^a   Schmidt, Stephen D ^a   Lifson, Jeffrey D ^e   Mascola, John R ^a   Nussenzweig, Michel C ^b,f   Martin, Malcolm A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10 1074; MONOCLONAL ANTIBODY 3BNC117; MONOCLONAL ANTIBODY VRC01; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS DNA; VIRUS RNA; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN FC FRAGMENT; NEUTRALIZING ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE;

ANTIBODY; DRUG; HEPATITIS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; MUTATION; RODENT; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TISSUE LEVEL; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IC50; IMMUNOPROPHYLAXIS; MALE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS TRANSMISSION; ANIMAL; BLOOD; CHEMISTRY; GENETICS; HALF LIFE TIME; HIV INFECTIONS; IMMUNOLOGY; MUTATION; PROTEIN TERTIARY STRUCTURE; TIME FACTOR; TRANSMISSION; VIROLOGY;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; FEMALE; HALF-LIFE; HIV ANTIBODIES; HIV INFECTIONS; IMMUNOGLOBULIN FC FRAGMENTS; MACACA MULATTA; MALE; MUTATION; PROTEIN STRUCTURE, TERTIARY; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TIME FACTORS;

EID: 84966389751     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature17677     Document Type: Article

References (33)

1. Baba, T. W. et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nature Med. 6, 200-206 (2000).
2. Hessell, A. J. et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nature Med. 15, 951-954 (2009).
3. Mascola, J. R. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Med. 6, 207-210 (2000).
4. Moldt, B. et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl Acad. Sci. USA 109, 18921-18925 (2012).
5. Nishimura, Y. et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J. Virol. 76, 2123-2130 (2002).
6. Parren, P. W. et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340-8347 (2001).
7. Pietzsch, J. et al. A mouse model for HIV-1 entry. Proc. Natl Acad. Sci. USA 109, 15859-15864 (2012).
8. Shibata, R. et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nature Med. 5, 204-210 (1999).
9. Ko, S. Y. et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514, 642-645 (2014).
10. Mouquet, H. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl Acad. Sci. USA 109, E3268-E3277 (2012).
11. Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637 (2011).
12. Zhou, T. et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817 (2010).
13. Burton, D. R., Mascola, J. R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nature Immunol. 16, 571-576 (2015).
14. Barouch, D. H. et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224-228 (2013).
15. Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487-491 (2015).
16. Klein, F. et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492, 118-122 (2012).
17. Shingai, M. et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503, 277-280 (2013).
18. Lynch, R. M. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319-206 (2015).
19. Rudicell, R. S. et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88, 12669-12682 (2014).
20. Saunders, K. O. et al. Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection. J. Virol. 89, 5895-5903 (2015).
21. Shingai, M. et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211, 2061-2074 (2014).
22. Patel, P. et al. Estimating per-act HIV transmission risk: a systematic review. AIDS 28, 1509-1519 (2014).
23. Fiore, A. E., Wasley, A., Bell, B. P. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Wkly Rep. 55, 1-23 (2006).
24. Graham, B. S., Ambrosino, D. M. History of passive antibody administration for prevention and treatment of infectious diseases. Curr. Opin. HIV AIDS 10, 129-134 (2015).
25. Shingai, M. et al. Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proc. Natl Acad. Sci. USA 109, 19769-19774 (2012).
26. Nishimura, Y. et al. Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. J. Virol. 84, 4769-4781 (2010).
27. Gautam, R. et al. Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. J. Virol. 86, 8516-8526 (2012).
28. West, A. P. Jr et al. Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proc. Natl Acad. Sci. USA 110, 10598-10603 (2013).
29. Hansen, S. G. et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527 (2011).
30. Ledgerwood, J. E. et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin. Exp. Immunol. 182, 289-301 (2015).
31. Endo, Y. et al. Short-and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus. J. Virol. 74, 6935-6945 (2000).
32. Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108-10125 (2005).
33. Wei, X. et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46, 1896-1905 (2002).